Search - tctmd.com

Displaying 41 - 60 of 105

Sort: Relevancy | Date

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

News Features

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

Michael O'Riordan

January 17, 2022

TCTMD’s Top 10 Most Popular Stories for December 2021

News Daily News

TCTMD’s Top 10 Most Popular Stories for December 2021

December 29, 2021

Trial of Cell Therapy for HF Misses Primary Endpoint, but Signals a Path Forward

News Conference News

Trial of Cell Therapy for HF Misses Primary Endpoint, but Signals a Path Forward

November 16, 2021

Switching to Tenecteplase for Stroke Thrombolysis May Boost Outcomes

News Daily News

Switching to Tenecteplase for Stroke Thrombolysis May Boost Outcomes

September 09, 2021

PRONOUNCE: No Difference in CVD Risks With Degarelix and Leuprolide for Prostate Cancer

News Conference News ESC 2021

PRONOUNCE: No Difference in CVD Risks With Degarelix and Leuprolide for Prostate Cancer

Michael O'Riordan

August 30, 2021

OMT Boosts Survival in Revascularized Patients at 10 Years

News Daily News

OMT Boosts Survival in Revascularized Patients at 10 Years

Michael O'Riordan

June 29, 2021

Subcutaneous GP IIb/IIIa Inhibitor in STEMI Is Fast, Potent in Early Study

News Conference News EuroPCR 2021

Subcutaneous GP IIb/IIIa Inhibitor in STEMI Is Fast, Potent in Early Study

May 18, 2021

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

News Daily News

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

Michael O'Riordan

March 03, 2021

Infective Endocarditis in IV Drug Users Doesn’t Always Match Expectations

News Daily News

Infective Endocarditis in IV Drug Users Doesn’t Always Match Expectations

February 01, 2021

Inclisiran Approved in Europe for Lowering LDL Cholesterol

News Daily News

Inclisiran Approved in Europe for Lowering LDL Cholesterol

Michael O'Riordan

December 11, 2020

Rilonacept Prevents Recurrent Pericarditis: RHAPSODY

News Conference News AHA 2020

Rilonacept Prevents Recurrent Pericarditis: RHAPSODY

November 17, 2020

COVID-19-Related Inflammatory Syndrome in Kids Needs Cardiac Follow-up

News Daily News

COVID-19-Related Inflammatory Syndrome in Kids Needs Cardiac Follow-up

June 10, 2020

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

News Conference News ACC 2020

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Yael L. Maxwell

April 06, 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

News Conference News ACC 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Michael O'Riordan

April 02, 2020

Inclisiran Data in NEJM Prompt Talk of What Comes Next

News Daily News

Inclisiran Data in NEJM Prompt Talk of What Comes Next

March 24, 2020

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

News Features

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

December 10, 2019

Calcium Conundrum: New Scores, Research Aim to Boost Outcomes in PAD Interventions

News Conference News VIVA 2019

Calcium Conundrum: New Scores, Research Aim to Boost Outcomes in PAD Interventions

November 13, 2019

Evolocumab Safe and Effective Out to 5 Years: OSLER-1

News Daily News

Evolocumab Safe and Effective Out to 5 Years: OSLER-1

Yael L. Maxwell

October 22, 2019

News Industry News

CeleCor Therapeutics Announces Positive First-in-Human Data of RUC-4, a Novel Subcutaneous Platelet GPIIb/IIIa Inhibitor, Presented at TCT 2019

September 25, 2019

ORION-11: Inclisiran Shows Promise, Safety in Largest Published Cohort

News Conference News ESC 2019

ORION-11: Inclisiran Shows Promise, Safety in Largest Cohort to Date

Yael L. Maxwell

September 03, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.